| Literature DB >> 27104969 |
Abstract
Eosinophils are suppressed by a new class of drugs targeting Interleukin-5 (IL-5), an eosinophil growth, activation, and survival factor. Humanized anti-IL-5 antibodies are effective in treating asthma patients with the severe eosinophilic form of the disease and are the first new class of asthma drugs approved in 12 years.Entities:
Year: 2016 PMID: 27104969 DOI: 10.1016/j.cell.2016.04.020
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582